Follow the people · Insider
Mark L. Jacobson
Mark L. Jacobson files insider transactions with the SEC as a chief operating officer of Axsome Therapeutics (AXSM). We hold 4 disclosed purchases and sales filed since 19 March 2020, 1 of them in the last 90 days.
- Files forAXSM
- Disclosed buys and sells4 in all, 1 in the last 90 days
- Last disclosure3 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 17 March 2020 — 3 September 2026Chief Operating Officer · Axsome Therapeutics (AXSM)61 Form 4 lines · source: SEC Form 4
Everything they disclosed
61 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 10,000 shares of Axsome TherapeuticsSEC Form 43 September 2026Common Stock · traded 3 September 2026 · filed 3 September 2026
- ▼ sold on the open market 10,000 shares of Axsome TherapeuticsSEC Form 43 September 2026Common Stock · traded 3 September 2026 · filed 3 September 2026
- exercised options over 10,000 shares of Axsome Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 3 September 2026 · filed 3 September 2026
- exercised options over 4,517 shares of Axsome TherapeuticsSEC Form 45 May 2026Common Stock · traded 4 May 2026 · filed 5 May 2026
- ▼ sold on the open market 4,517 shares of Axsome TherapeuticsSEC Form 45 May 2026Common Stock · traded 4 May 2026 · filed 5 May 2026
- exercised options over 233 shares of Axsome TherapeuticsSEC Form 45 May 2026Common Stock · traded 5 May 2026 · filed 5 May 2026
- ▼ sold on the open market 233 shares of Axsome TherapeuticsSEC Form 45 May 2026Common Stock · traded 5 May 2026 · filed 5 May 2026
- exercised options over 4,517 shares of Axsome Therapeutics (a derivative holding)SEC Form 45 May 2026Stock Option (Right to Buy) · traded 4 May 2026 · filed 5 May 2026
- exercised options over 233 shares of Axsome Therapeutics (a derivative holding)SEC Form 45 May 2026Stock Option (Right to Buy) · traded 5 May 2026 · filed 5 May 2026
- was granted 8,669 shares of Axsome Therapeutics (a derivative holding)SEC Form 423 April 2026Performance Stock Units · traded 21 April 2026 · filed 23 April 2026
- exercised options over 35,378 shares of Axsome TherapeuticsSEC Form 427 February 2026Common Stock · traded 26 February 2026 · filed 27 February 2026
- ▼ sold on the open market 35,378 shares of Axsome TherapeuticsSEC Form 427 February 2026Common Stock · traded 26 February 2026 · filed 27 February 2026
- exercised options over 35,378 shares of Axsome Therapeutics (a derivative holding)SEC Form 427 February 2026Stock Option (Right to Buy) · traded 26 February 2026 · filed 27 February 2026
- exercised options over 35,378 shares of Axsome Therapeutics (a derivative holding)SEC Form 427 February 2026Stock Option (Right to Buy) · traded 26 February 2026 · filed 27 February 2026
- exercised options over 35,378 shares of Axsome TherapeuticsSEC Form 427 February 2026Common Stock · traded 26 February 2026 · filed 27 February 2026
- ▼ sold on the open market 35,378 shares of Axsome TherapeuticsSEC Form 427 February 2026Common Stock · traded 26 February 2026 · filed 27 February 2026
- was granted 19,663 shares of Axsome Therapeutics (a derivative holding)SEC Form 427 February 2026Restricted Stock Units · traded 26 February 2026 · filed 27 February 2026
- was granted 19,663 shares of Axsome Therapeutics (a derivative holding)SEC Form 427 February 2026Restricted Stock Units · traded 26 February 2026 · filed 27 February 2026
- exercised options over 10,000 shares of Axsome Therapeutics (a derivative holding)SEC Form 422 September 2025Stock Option (Right to Buy) · traded 22 September 2025 · filed 22 September 2025
- exercised options over 10,000 shares of Axsome TherapeuticsSEC Form 422 September 2025Common Stock · traded 22 September 2025 · filed 22 September 2025
- ▼ sold on the open market 10,000 shares of Axsome TherapeuticsSEC Form 422 September 2025Common Stock · traded 22 September 2025 · filed 22 September 2025
- exercised options over 25,000 shares of Axsome Therapeutics (a derivative holding)SEC Form 417 September 2025Stock Option (Right to Buy) · traded 16 September 2025 · filed 17 September 2025
- exercised options over 15,000 shares of Axsome Therapeutics (a derivative holding)SEC Form 417 September 2025Stock Option (Right to Buy) · traded 16 September 2025 · filed 17 September 2025
- ▼ sold on the open market 5,783 shares of Axsome TherapeuticsSEC Form 417 September 2025Common Stock · traded 16 September 2025 · filed 17 September 2025
- exercised options over 25,000 shares of Axsome TherapeuticsSEC Form 417 September 2025Common Stock · traded 16 September 2025 · filed 17 September 2025
- exercised options over 15,000 shares of Axsome TherapeuticsSEC Form 417 September 2025Common Stock · traded 16 September 2025 · filed 17 September 2025
- ▼ sold on the open market 40,000 shares of Axsome TherapeuticsSEC Form 417 September 2025Common Stock · traded 16 September 2025 · filed 17 September 2025
- exercised options over 25,000 shares of Axsome Therapeutics (a derivative holding)SEC Form 410 June 2025Stock Option (Right to Buy) · traded 9 June 2025 · filed 10 June 2025
- exercised options over 25,000 shares of Axsome TherapeuticsSEC Form 410 June 2025Common Stock · traded 9 June 2025 · filed 10 June 2025
- ▼ sold on the open market 25,000 shares of Axsome TherapeuticsSEC Form 410 June 2025Common Stock · traded 9 June 2025 · filed 10 June 2025
- exercised options over 20,673 shares of Axsome Therapeutics (a derivative holding)SEC Form 428 May 2025Stock Option (Right to Buy) · traded 27 May 2025 · filed 28 May 2025
- exercised options over 20,000 shares of Axsome Therapeutics (a derivative holding)SEC Form 428 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 28 May 2025
- exercised options over 20,673 shares of Axsome TherapeuticsSEC Form 428 May 2025Common Stock · traded 27 May 2025 · filed 28 May 2025
- ▼ sold on the open market 20,673 shares of Axsome TherapeuticsSEC Form 428 May 2025Common Stock · traded 27 May 2025 · filed 28 May 2025
- exercised options over 20,000 shares of Axsome TherapeuticsSEC Form 428 May 2025Common Stock · traded 28 May 2025 · filed 28 May 2025
- ▼ sold on the open market 20,000 shares of Axsome TherapeuticsSEC Form 428 May 2025Common Stock · traded 28 May 2025 · filed 28 May 2025
- was granted 10,875 shares of Axsome Therapeutics (a derivative holding)SEC Form 425 February 2025Employee Stock Option (Right to Buy) · traded 21 February 2025 · filed 25 February 2025
- was granted 10,769 shares of Axsome Therapeutics (a derivative holding)SEC Form 425 February 2025Restricted Stock Units · traded 21 February 2025 · filed 25 February 2025
- was granted 10,769 shares of Axsome Therapeutics (a derivative holding)SEC Form 425 February 2025Performance Stock Units · traded 24 February 2025 · filed 25 February 2025
- exercised options over 47,739 shares of Axsome Therapeutics (a derivative holding)SEC Form 49 August 2024Stock Option (Right to Buy) · traded 9 August 2024 · filed 9 August 2024
- exercised options over 47,739 shares of Axsome TherapeuticsSEC Form 49 August 2024Common Stock · traded 9 August 2024 · filed 9 August 2024
- ▼ sold on the open market 47,739 shares of Axsome TherapeuticsSEC Form 49 August 2024Common Stock · traded 9 August 2024 · filed 9 August 2024
- exercised options over 13,693 shares of Axsome Therapeutics (a derivative holding)SEC Form 429 May 2024Stock Option (Right to Buy) · traded 29 May 2024 · filed 29 May 2024
- exercised options over 13,693 shares of Axsome TherapeuticsSEC Form 429 May 2024Common Stock · traded 29 May 2024 · filed 29 May 2024
- ▼ sold on the open market 7,910 shares of Axsome TherapeuticsSEC Form 429 May 2024Common Stock · traded 29 May 2024 · filed 29 May 2024
- exercised options over 24,662 shares of Axsome Therapeutics (a derivative holding)SEC Form 41 April 2024Stock Option (Right to Buy) · traded 1 April 2024 · filed 1 April 2024
- exercised options over 24,662 shares of Axsome TherapeuticsSEC Form 41 April 2024Common Stock · traded 1 April 2024 · filed 1 April 2024
- ▼ sold on the open market 24,662 shares of Axsome TherapeuticsSEC Form 41 April 2024Common Stock · traded 1 April 2024 · filed 1 April 2024
- was granted 32,825 shares of Axsome Therapeutics (a derivative holding)SEC Form 429 February 2024Employee Stock Option (Right to Buy) · traded 27 February 2024 · filed 29 February 2024
- was granted 18,027 shares of Axsome Therapeutics (a derivative holding)SEC Form 429 February 2024Restricted Stock Units · traded 27 February 2024 · filed 29 February 2024
- was granted 41,424 shares of Axsome Therapeutics (a derivative holding)SEC Form 46 March 2023Employee Stock Option (Right to Buy) · traded 2 March 2023 · filed 6 March 2023
- was granted 23,491 shares of Axsome Therapeutics (a derivative holding)SEC Form 46 March 2023Restricted Stock Units · traded 2 March 2023 · filed 6 March 2023
- was granted 89,405 shares of Axsome Therapeutics (a derivative holding)SEC Form 48 March 2022Employee Stock Option (Right to Buy) · traded 4 March 2022 · filed 8 March 2022
- was granted 47,990 shares of Axsome Therapeutics (a derivative holding)SEC Form 48 March 2022Restricted Stock Units · traded 4 March 2022 · filed 8 March 2022
- was granted 41,638 shares of Axsome Therapeutics (a derivative holding)SEC Form 415 November 2021Employee Stock Option (Right to Buy) · traded 12 November 2021 · filed 15 November 2021
- was granted 41,638 shares of Axsome Therapeutics (a derivative holding)SEC Form 49 March 2021Employee Stock Option (Right to Buy) · traded 5 March 2021 · filed 9 March 2021
- was granted 22,163 shares of Axsome Therapeutics (a derivative holding)SEC Form 49 March 2021Restricted Stock Units · traded 5 March 2021 · filed 9 March 2021
- was granted 48,237 shares of Axsome Therapeutics (a derivative holding)SEC Form 423 December 2020Employee Stock Option (Right to Buy) · traded 17 March 2020 · filed 23 December 2020
- was granted 14,767 shares of Axsome Therapeutics (a derivative holding)SEC Form 423 December 2020Restricted Stock Units · traded 17 March 2020 · filed 23 December 2020
- was granted 60,880 shares of Axsome Therapeutics (a derivative holding)SEC Form 419 March 2020Employee Stock Option (Right to Buy) · traded 17 March 2020 · filed 19 March 2020
- was granted 18,645 shares of Axsome Therapeutics (a derivative holding)SEC Form 419 March 2020Restricted Stock Units · traded 17 March 2020 · filed 19 March 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.